Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal


Author index

Page Path
HOME > Browse > Author index
Oak-Kee Hong  (Hong OK) 1 Article
Angiotensin II Inhibits Insulin Binding to Endothelial Cells
Su-Jin Oh, Won-Chul Ha, Jee-In Lee, Tae-Seo Sohn, Ji-Hyun Kim, Jung-Min Lee, Sang-Ah Chang, Oak-Kee Hong, Hyun-Shik Son
Diabetes Metab J. 2011;35(3):243-247.   Published online June 30, 2011
  • 4,038 View
  • 24 Download
  • 6 Crossref
AbstractAbstract PDFPubReader   

Insulin-mediated glucose uptake in insulin target tissues is correlated with interstitial insulin concentration, rather than plasma insulin concentration. Therefore, insulin delivery to the interstitium of target tissues is very important, and the endothelium may also play an important role in the development of insulin resistance.


After treating bovine aortic endothelial cells with angiotensin II (ATII), we observed the changes in insulin binding capacity and the amounts of insulin receptor (IR) on the cell membranes and in the cytosol.


After treatment of 10-7M ATII, insulin binding was decreased progressively, up to 60% at 60 minutes (P<0.05). ATII receptor blocker (eprosartan) dose dependently improved the insulin binding capacity which was reduced by ATII (P<0.05). At 200 µM, eprosartan fully restored insulin binding capacity, althogh it resulted in only a 20% to 30% restoration at the therapeutic concentration. ATII did not affect the total amount of IR, but it did reduce the amount of IR on the plasma membrane and increased that in the cytosol.


ATII decreased the insulin binding capacity of the tested cells. ATII did not affect the total amount of IR but did decrease the amount of IR on the plasma membrane. Our data indicate that ATII decreases insulin binding by translocating IR from the plasma membrane to the cytosol. The binding of insulin to IR is important for insulin-induced vasodilation and transendothelial insulin transport. Therefore, ATII may cause insulin resistance through this endothelium-based mechanism.


Citations to this article as recorded by  
  • Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle
    Dino Premilovac, Emily Attrill, Stephen Rattigan, Stephen M Richards, Jeonga Kim, Michelle A Keske
    Cardiovascular Research.2019; 115(3): 590.     CrossRef
  • Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells
    Yang Yang, Caiyu Chen, Chunjiang Fu, Zaicheng Xu, Cong Lan, Yongchun Zeng, Zhi Chen, Pedro A. Jose, Ye Zhang, Chunyu Zeng
    Journal of the American Society of Hypertension.2018; 12(2): 135.     CrossRef
  • Endothelial function, its relation to arterial hypertension and the possibility of its modulation
    Vladislav Biel, Jan Novák, Luděk Pluháček, Jiří Špác
    Vnitřní lékařství.2018; 64(7-8): 762.     CrossRef
  • Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease
    Juan M. Saavedra
    Cellular and Molecular Neurobiology.2016; 36(2): 259.     CrossRef
  • Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats
    Mohamed A. Morsy, Gehan H. Heeba, Magda E. Mahmoud
    European Journal of Pharmacology.2015; 750: 90.     CrossRef
  • Metabolic actions of angiotensin II and insulin: A microvascular endothelial balancing act
    Ranganath Muniyappa, Sahzene Yavuz
    Molecular and Cellular Endocrinology.2013; 378(1-2): 59.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer